Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor

Journal of Thoracic Oncology

Volumn 7, Issue 16 SUPPL. 5, 2012, Pages

  Sadiq, Ahad A ^a   Salgia, Ravi ^a  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CABOZANTINIB; CAPECITABINE; CETUXIMAB; CISPLATIN; CRIZOTINIB; DOCETAXEL; EPIRUBICIN; ERLOTINIB; FORETINIB; LY 2801653; ONARTUZUMAB; PLACEBO; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RILOTUMUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TEMOZOLOMIDE; TIVANTINIB; UNCLASSIFIED DRUG;

ALOPECIA; ARTICLE; CANCER RESISTANCE; CANCER THERAPY; DRUG DOSE ESCALATION; DRUG POTENTIATION; HUMAN; KIDNEY CARCINOMA; LIGAND BINDING; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84870398856     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31826df03e     Document Type: Article

References (18)

1. Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984;311:29-33.
2. Park S, Choi YL, Sung CO, et al. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol 2012;27:197-207.
3. Cepero V, Sierra JR, Corso S, et al. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res 2010;70:7580-7590.
4. Tiedt R, Degenkolbe E, Furet P, et al. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. Cancer Res 2011;71:5255-5264.
5. Catenacci DV, Henderson L, Xiao SY, et al. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov 2011;1:573-579.
6. Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci 1998;111 (Pt 2):237-247.
7. Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006;12(20 Pt 1):6144-6152.
8. Jin H, Yang R, Zheng Z, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008;68:4360-4368.
9. Park S, Choi YL, Sung CO, et al. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol 2012;27:197-207.
10. Spigel DR, Burris HA III, Greco FA, et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011;29:2582-2589.
11. Eathiraj S, Palma R, Hirschi M, et al. A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases: discovery of ATP-independent inhibitors of fibroblast growth factor receptor. J Biol Chem 2011;286:20677-20687.
12. Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011;29:3307-3315.
13. Wei J, Wang C, Qin YW, et al. JAK2 V617F positive essential thrombocythemia developing in a patient with CD5-chronic lymphocytic leukemia. Chin Med J 2012;125:2076-2079.
14. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011;6: 942-946.
15. Liu L, Shi H, Liu Y, et al. Synergistic effects of foretinib with HER-targeted agents in MET and HER1-or HER2-coactivated tumor cells. Mol Cancer Ther 2011;10:518-530.
16. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10:2298-2308.
17. Giordano S. Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer. Curr Opin Mol Ther 2009;11:448-455.
18. Jun HT, Sun J, Rex K, et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 2007;13(22 Pt 1):6735-6742.